ReviewDrugs2010
Pharmacoeconomic considerations in the treatment of multiple sclerosis.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.PharmacoEconomics · 2021Pooled it
- Cost of Illness of Multiple Sclerosis - A Systematic Review.PloS one · 2016Pooled it
- Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.Neurology and therapy · 2022Article
- Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies.Frontiers in neurology · 2022Review
- Therapeutic adherence and coping strategies in patients with multiple sclerosis: An observational study.Medicine · 2019Observational
- Body image in multiple sclerosis patients: a descriptive review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Review
- An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Patient preference and adherence · 2017Article
- Review
- Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Drugs · 2013Review
- Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.PharmacoEconomics · 2013Review
- Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
- Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Cost-effectiveness of disease-modifying therapies in multiple sclerosis.Current neurology and neuroscience reports · 2012Review
- Disease-modifying therapies in multiple sclerosis in Latin America.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a disorder that incurs high costs to individuals, health systems and society as a whole. A growing number of studies have measured the costs of MS and assessed the cost effectiveness of different treatments. This review summarizes the evidence from these studies. Electronic databases were searched and a total of 51 studies were included, 32 of which were cost-of-illness studies. The cost-of-illness studies took different perspectives (health service or societal) and the annual costs per person with MS ranged between $US6511 and $US77,938 (year of cost 2008). Economic evaluations of interferon (IFN)-beta-1a, IFNbeta-1b, glatiramer acetate, natalizumab, mitoxantrone and cyclophosphamide were identified. The results of the cost effectiveness of drug interventions were mixed. Most results comparing a drug with placebo related to IFNbeta-1b and the results usually revealed cost-effectiveness ratios that were above usual willingness-to-pay thresholds of public decision makers. The limited evidence on glatiramer acetate suggests that this may be cost effective. Head-to-head drug comparisons produced varying results, although the findings for natalizumab appear favourable compared with other drugs. Further trial-based comparisons are required to increase the evidence base regarding drug treatments for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.